<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871048</url>
  </required_header>
  <id_info>
    <org_study_id>19PH229</org_study_id>
    <secondary_id>2020-A02976-33</secondary_id>
    <nct_id>NCT04871048</nct_id>
  </id_info>
  <brief_title>Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia</brief_title>
  <acronym>CANNAPSYSTIM</acronym>
  <official_title>Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia A Randomized Controlled Double-blind Exploratory Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabis use disorder is a frequent comorbidity of schizophrenia, associated with increased&#xD;
      symptoms and less adherence to therapy. Validated care has limited effectiveness in this&#xD;
      population and development of new management strategies seems necessary. Transcranial direct&#xD;
      current stimulation (tDCS) has shown beneficial effects in both schizophrenia, substance use&#xD;
      disorder and, in a less extent, in nicotine addiction in schizophrenic subjects. It is&#xD;
      interesting to test if that 10 sessions of anodal stimulation of the right dorsolateral&#xD;
      prefrontal cortex (DLPFC) and cathodal stimulation of the medial prefrontal cortex (MPFC) (by&#xD;
      increasing control and modulating reward system), will reduce, in 110 schizophrenic subjects,&#xD;
      cannabis consumption, and secondly craving, addiction severity, schizophrenic symptoms and&#xD;
      improve global functioning. It is possible that these clinical effects will be associated&#xD;
      with changes in certain cognitive functions and cerebral connectivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge&#xD;
      electrodes soaked in a saline solution. Electrodes will be placed in accordance with the&#xD;
      international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode&#xD;
      over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation&#xD;
      sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.&#xD;
&#xD;
      The control group will receive the sham stimulation following the same regimen, using the&#xD;
      sham procedure which has been developed by the manufacturer of the tDCS material, allowing&#xD;
      sensations to be felt in the scalp which are the equivalent to those of the active&#xD;
      stimulation. The same device will be used for both the sham and the active procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.&#xD;
The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>active tDCS stimulation. Patients will receive 10 sessions of tDCS over 5 consecutive days, at a frequency of 2 sessions per day spaced at least two hours apart, at an intensity of 2mA, for 20 minutes each.&#xD;
tDCS placebo stimulation. Patients will receive 10 sessions of tDCS over 5 consecutive days, at a frequency of 2 sessions per day spaced at least two hours apart, following an identical procedure (tracking, then wearing the device for 20 minutes) but with actual stimulation provided during the first 40 seconds.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>cannabis use</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage change in cannabis use before and after tDCS treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cannabis use</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage change in cannabis use before and after 3 months tDCS treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in craving scores</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Marijuana Craving Questionnaire score (minimum =12, maximum = 84). The higher the score, the greater the craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hospitalization(s) during the 6 months after tDCS sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of structural cerebral connectivity</measure>
    <time_frame>3 months</time_frame>
    <description>Cerebral MRI (only for a subgroup of patients) : Diffusion of water at the white matter level for the evaluation of structural brain connectivity in DTI mode (diffusion tensor) on</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of structural and functional cerebral connectivity</measure>
    <time_frame>3 months</time_frame>
    <description>Cerebral MRI (only for a subgroup of patients) : Functional connectivity index evaluated by resting state default mode network (MRI) for the evaluation of functional brain connectivity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cannabis-Induced Disorder</condition>
  <arm_group>
    <arm_group_label>active tDCS stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial direct current stimulation tDCS-Stimulation will be performed using a Neurocan DC-Stimulator Plus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Transcranial direct current stimulation tDCS-The control group will receive the sham stimulation following the same regimen, using the sham procedure .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) active</intervention_name>
    <description>Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.</description>
    <arm_group_label>active tDCS stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation (tDCS) non active</intervention_name>
    <description>The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.</description>
    <arm_group_label>sham tDCS stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia diagnostic according to DSM (Diagnostic and Statistical Manual of mental&#xD;
             disorder) 5 criteria, without change in psychotropic treatment since at least 4 weeks&#xD;
&#xD;
          -  Moderate to severe cannabis use disorder according to DSM 5 criteria and active&#xD;
             consumption during the last 7 days&#xD;
&#xD;
          -  Subjects motivated to reduce or quit their cannabis consumption&#xD;
&#xD;
          -  Patients with ambulatory compulsory care may be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other substance use disorder, excluding nicotine, according to DSM 5 criteria&#xD;
&#xD;
          -  Other current psychiatric disorder according to DSM 5 criteria, excluding personality&#xD;
             disorder&#xD;
&#xD;
          -  Inpatient hospitalization&#xD;
&#xD;
          -  History of head injury, neurological disorder with cerebral consequence or severe&#xD;
             unstable somatic disorder&#xD;
&#xD;
          -  Pregnancy or no contraception&#xD;
&#xD;
          -  Contraindications for tDCS and/or MRI (implanted material, uncontrolled epilepsy,&#xD;
             intracranial hypertension)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurelia GAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurelia GAY, MD</last_name>
    <phone>(0)4 77 82 88 50</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelia.gay@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Béatrice DEYGAS</last_name>
    <email>beatrice.deygas@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Le Vinatier Service universitaire d'addictologie de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin ROLLAND, PHD</last_name>
      <phone>(0)437915075</phone>
      <phone_ext>+33</phone_ext>
      <email>benjamin.rolland@ch-le-vinatier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Service d'Addictologie et Pathologies Duelles</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Georges BROUSSE, PHD</last_name>
      <phone>(0)473752072</phone>
      <phone_ext>+33</phone_ext>
      <email>gbrousse@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand Service de Psychiatrie</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Michel LLORCA, PHD</last_name>
      <phone>(0)473752125</phone>
      <phone_ext>+33</phone_ext>
      <email>pmllorca@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hospitalo-Universitaire d'Addictologie CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoit TROJAK, PHD</last_name>
      <phone>(0)380293769</phone>
      <phone_ext>+33</phone_ext>
      <email>benoit.trojak@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pôle de Psychiatrie Neurologie et Rééducation</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mircea POLOSAN, PHD</last_name>
      <phone>(0)476765383</phone>
      <phone_ext>+33</phone_ext>
      <email>mpolosan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint-Cyr-au-Mont-d'Or service de psychiatrie</name>
      <address>
        <city>Saint-Cyr-au-Mont-d'Or</city>
        <zip>69450</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florian LE CAMUS, MD</last_name>
      <phone>(0)472421183</phone>
      <phone_ext>+33</phone_ext>
      <email>flecamus@ch-st-cyr69.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Isère</name>
      <address>
        <city>Saint-Égrève</city>
        <zip>38120</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clément DONDE, MD</last_name>
      <phone>(0)476564340</phone>
      <phone_ext>+33</phone_ext>
      <email>cdonde@ch-alpes-isere.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dorsolateral prefrontal cortex</keyword>
  <keyword>medial prefrontal cortex</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>cannabis-induced disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

